Literature DB >> 17721703

Key clinical issues in renal cancer: a challenge for proteomics.

Rosamonde E Banks1, Rachel A Craven, Patricia Harnden, Sanjeev Madaan, Adrian Joyce, Peter J Selby.   

Abstract

Renal cancer has many clinical challenges which proteomics is ideally placed to address. The issues cover all aspects of the disease including diagnosis, prognosis, treatment selection and monitoring to detect metastatic disease. In all cases novel biomarkers would considerably help in clinical management and with the relative resistance to conventional chemotherapy and radiotherapy, a better understanding of the underlying pathogenesis may contribute to the much needed development of novel therapeutic targets and the better use of promising new anti-angiogenic treatments. This review briefly highlights some of the clinical issues and describes proteomics-based approaches generally, before focussing on reviewing the proteomic studies to date in this area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721703     DOI: 10.1007/s00345-007-0199-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  108 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.

Authors:  Rachel A Craven; Sarah Hanrahan; Nick Totty; Patricia Harnden; Anthea J Stanley; Eamonn R Maher; Adrian L Harris; William S Trimble; Peter J Selby; Rosamonde E Banks
Journal:  Proteomics       Date:  2006-07       Impact factor: 3.984

3.  Identification of tumor antigens in renal cell carcinoma by serological proteome analysis.

Authors:  C S Klade; T Voss; E Krystek; H Ahorn; K Zatloukal; K Pummer; G R Adolf
Journal:  Proteomics       Date:  2001-07       Impact factor: 3.984

4.  Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma.

Authors:  C Sarto; S Frutiger; F Cappellano; J C Sanchez; G Doro; F Catanzaro; G J Hughes; D F Hochstrasser; P Mocarelli
Journal:  Electrophoresis       Date:  1999-11       Impact factor: 3.535

5.  Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics.

Authors:  Kerstin Junker; Jana Gneist; Christian Melle; Dominik Driesch; Joerg Schubert; Uwe Claussen; Ferdinand Von Eggeling
Journal:  Int J Mol Med       Date:  2005-02       Impact factor: 4.101

6.  Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination.

Authors:  Uwe Zimmermann; Stefan Balabanov; Jürgen Giebel; Steffen Teller; Heike Junker; Dieter Schmoll; Chris Protzel; Christian Scharf; Britta Kleist; Reinhard Walther
Journal:  Cancer Lett       Date:  2004-06-08       Impact factor: 8.679

7.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

Authors:  Rosamonde E Banks; Prasanna Tirukonda; Claire Taylor; Nick Hornigold; Dewi Astuti; Dena Cohen; Eamonn R Maher; Anthea J Stanley; Patricia Harnden; Adrian Joyce; Margaret Knowles; Peter J Selby
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

8.  Preliminary experience using high intensity focused ultrasound for the treatment of patients with advanced stage renal malignancy.

Authors:  Feng Wu; Zhi-Biao Wang; Wen-Zhi Chen; Jin Bai; Hui Zhu; Tian-Yu Qiao
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

Review 9.  Renal adenoma and oncocytoma.

Authors:  M R Licht
Journal:  Semin Urol Oncol       Date:  1995-11

10.  Human agmatinase is diminished in the clear cell type of renal cell carcinoma.

Authors:  Kerstin Dallmann; Heike Junker; Stefan Balabanov; Uwe Zimmermann; Jürgen Giebel; Reinhard Walther
Journal:  Int J Cancer       Date:  2004-01-20       Impact factor: 7.396

View more
  5 in total

1.  Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker.

Authors:  Florence Defresne; Caroline Bouzin; Céline Guilbaud; Marc Dieu; Edouard Delaive; Carine Michiels; Martine Raes; Olivier Feron
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

2.  Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma.

Authors:  Barbara Seliger; Sven P Dressler; Ena Wang; Roland Kellner; Christian V Recktenwald; Friedrich Lottspeich; Francesco M Marincola; Maja Baumgärtner; Derek Atkins; Rudolf Lichtenfels
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

3.  Protein expression profiling in the spectrum of renal cell carcinomas.

Authors:  Vladimir A Valera; Elsa Li-Ning-T; Beatriz A Walter; David D Roberts; W M Linehan; Maria J Merino
Journal:  J Cancer       Date:  2010-10-14       Impact factor: 4.207

4.  Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis.

Authors:  Rudolf Lichtenfels; Sven P Dressler; Monica Zobawa; Christian V Recktenwald; Angelika Ackermann; Derek Atkins; Michael Kersten; Andrea Hesse; Maria Puttkammer; Friedrich Lottspeich; Barbara Seliger
Journal:  Mol Cell Proteomics       Date:  2009-09-14       Impact factor: 5.911

5.  Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.

Authors:  Song Wu; Yong Wang; Liang Sun; Zhiling Zhang; Zhimao Jiang; Zike Qin; Hui Han; Zhuowei Liu; Xianxin Li; Aifa Tang; Yaoting Gui; Zhiming Cai; Fangjian Zhou
Journal:  BMC Cancer       Date:  2011-09-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.